SCHEMBL3602028

SCHEMBL3602028

Cc1ccc(C(=O)NC2CC2)cc1Nc1nc(-c2cccc(CO)c2)c(C(=O)NCc2ccccc2)s1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.48
MAPK11 Q15759 8/20 0.48
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
MAPK13 O15264 3/20 0.41
MAPK12 P53778 3/20 0.41
SMYD3 Q9H7B4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3345904 0.94 MAPK14 (0.50) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL27635999 0.94 MAPK14 (0.50) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3317676 0.93 MAPK14 (0.47) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3351894 0.93 MAPK14 (0.52) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3317125 0.93 MAPK14 (0.49) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3346382 0.93 MAPK14 (0.49) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3321574 0.92 MAPK14 (0.47) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3594171 0.92 MAPK14 (0.47) MAPK14MAPK11MAPTTP53LMNA
SCHEMBL3349382 0.91 MAPK14 (0.55) MAPK14MAPK11MAPTTP53RXFP1
SCHEMBL3345801 0.91 MAPK14 (0.47) MAPK14MAPK11MAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 US claimed
CN-1829513-A 5-membered heterocycle-based p-38 inhibitors NOVARTIS AG (CH) 2006-09-06 CN claimed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 US disclosed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004298-A1 P-38 INHIBITORS MAPK8, MAPK1, MAP3K8 MAPK14 21/4885MAPK11 38/4885MAPT 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.